Sickle Cell Disease Treatment Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)
Description
The sickle cell disease treatment market was valued at USD 5.38 Billion in 2024 driven by the rising prevalence of sickle cell disease and advancements in treatment options across the 8 major markets. It is expected to grow at a CAGR of 16.90% during the forecast period 2025-2034 and attain a market value of USD 25.64 Billion by 2034.
Sickle Cell Disease Treatment Market Overview
Treatment for sickle cell disease (SCD) aims to address symptoms such as anemia, pain, and organ damage. Sickle cell disease is a hereditary blood condition characterized by the presence of abnormal hemoglobin S that creates stiff, sickle-shaped red blood cells, resulting in obstruction and decreased oxygen supply to tissues. Mutations in the HBB gene result in deformed red blood cells, leading to aggregation and obstruction in blood vessels.
Managing sickle cell disease requires a comprehensive strategy that includes medication, blood transfusions, pain relief, and possible cures such as bone marrow transplants and new gene therapies. Patients frequently experience multiple hospital stays and need ongoing care to address the symptoms and complications linked to the illness.
In complicated cases of sickle cell disease, bone marrow or stem cell transplants may be needed for potential treatments. New possibilities are presented by emerging treatments such as gene therapies, voxelotor, and crizanlizumab. Several factors such as the rising patient population, significant investment from pharmaceutical companies, and an increasing focus on targeted therapies are likely to positively influence the market dynamics in the coming years.
Sickle Cell Disease Treatment Market Growth Drivers
Increasing Prevalence of Sickle Cell Disease Drives Market Growth
The increasing occurrence of sickle cell disease is fueling expansion in the market. Developed countries such as the United States and Europe also experience substantial occurrences because of migration and diversity. The Centers for Disease Control and Prevention’s May 2024 report states that sickle cell disease impacts around 100,000 people in the United States, out of which over 90% are non-Hispanic Black/African Americans and 3%-9% are Hispanics/Latinos. Life expectancy for those with sickle cell disease in the US is 20 years less than average. The need for innovative therapies and long-term care is growing due to the rising impact of the disease on children and adolescents, which is expected to lead to an increased demand for effective treatments.
Advancements in Gene Therapy and Technology are Likely to Boost Sickle Cell Disease Treatment Market Demand
Advancements in gene therapy and gene-editing techniques such as CRISPR-Cas9 are revolutionizing the treatment of sickle cell disease. In December 2023, the FDA approved Casgevy and Lyfgenia as the first cell-based gene therapies for sickle cell disease in patients 12 years and older. Casgevy also marks the first FDA-approved treatment utilizing novel genome editing technology. These treatments provide the potential for a permanent cure by altering or substituting the faulty hemoglobin gene. LentiGlobin and CRISPR-based treatments offer hope for patients with sickle cell disease with promising outcomes. With gene therapy becoming more available, the market is forecasted to expand quickly.
Sickle Cell Disease Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Shift Toward Curative Therapies
The market for treating sickle cell disease is moving towards curative methods such as stem cell transplantation instead of focusing on managing symptoms. Research is also exploring bone marrow and stem cell transplants as potential cures, despite obstacles such as limited donor availability. These developments are expected to drive market growth in the forecast period.
Increased Research on Hemoglobin Modifiers
There is a growing focus on studying hemoglobin modifiers such as voxelotor to change abnormal hemoglobin and decrease the deformation of red blood cells. More research is being done to create enhanced next-generation modifiers with better effectiveness and reduced side effects, broadening treatment choices for those with sickle cell disease. Focusing on modifying hemoglobin provides a less invasive option that is anticipated to make a big impact on the market for treating sickle cell disease, as opposed to gene and cell therapies.
Rising Interest in Combination Therapies
Combination treatments are being widely used in managing sickle cell disease to tackle its intricate characteristics. These treatments, including hydroxyurea, voxelotor, and crizanlizumab, focus on various facets of the illness to decrease vaso-occlusive episodes and lessen organ harm. Pharmaceutical companies are prioritizing clinical trials to investigate the synergistic impacts of these combinations, which is likely to aid in market growth.
Growing Demand for Pain Management Solutions
Effective pain control is essential in managing sickle cell disease as frequent crises result in intense pain. Recent treatments are focused on decreasing the frequency of pain, while non-drug methods like cognitive behavioral therapy are becoming more popular. These ground-breaking treatments are anticipated to have a positive impact on enhancing the clinical outcomes of patients with sickle cell disease.
Sickle Cell Disease Treatment Market Segmentation
The EMR’s report titled “Sickle Cell Disease Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment
Market Segmentation Based on the Treatment to Witness Growth
Based on the treatment, the market is divided into pharmacotherapy, blood transfusions, bone marrow/ stem cell transplantation, and other supportive therapies. Out of these, pharmacotherapy is expected to dominate the market because of its effectiveness, widespread availability, and cost-effectiveness. Medications such as hydroxyurea have been utilized for many years to treat symptoms of sickle cell disease. The management of sickle cell disease still heavily relies on medication, as other more invasive treatments such as bone marrow transplantation have limitations.
Market Share Based on Disease Type
Based on the disease type, the market is segmented into sickle cell anaemia, sickle hemoglobin-C disease, sickle beta-thalassemia, and others. Sickle cell anemia is the most prevalent and serious type of sickle cell disease, impacting many patients. Individuals with this disease deal with serious complications like painful crises and organ damage, leading to the need for extensive medical care.
Sickle Cell Disease Treatment Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
The United States is expected to dominate the market powered by government initiatives such as the National Sickle Cell Disease Program and newborn screening, which have enhanced the ability to diagnose and provide treatment at an early stage. Further, the market growth in the region is propelled by high healthcare spending and support from advocacy groups.
EU-4 and the United Kingdom are also poised to have a significant market share. Newborn screening and extensive healthcare services support individuals with sickle cell disease in the EU-4 (Germany, France, Italy, Spain) and the United Kingdom. The United Kingdom's NHS provides specialized medical services, as gene therapy research advances.
Additionally, the markets in Japan and India are rapidly expanding. Japan puts more emphasis on studying different genetic disorders and allocates substantial resources into researching gene therapy, while India deals with a high burden of sickle cell disease and works to enhance screening and access to treatment. The rise in strategic collaborations along with significant research funding is predicted to boost the development of India's sickle cell disease market in the forecast period.
Leading Players in the Sickle Cell Disease Treatment Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Novartis AG
Novartis AG is a Swiss pharmaceutical corporation that focuses on healthcare, producing prescription and generic drugs, as well as eye care products. Their products treat various diseases such as cancer, cardiovascular conditions, and respiratory illnesses. In April 2024, the FDA approved Novartis' Adakveo to reduce pain events in individuals with sickle cell disease. This medication helps decrease the frequency of vaso-occlusive crises in adults and children over 16 years old.
Bluebird Bio, Inc.
Bluebird Bio, Inc. is a biotechnology company based in Massachusetts. In December 2023, the company received FDA approval for LYFGENIA (lovo-cel) to treat sickle cell disease in patients aged 12 and older with a history of vaso-occlusive events. LYFGENIA is a one-time gene therapy designed to address the root cause of the disease and resolve vaso-occlusive events.
Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. develops treatments for rare diseases. In February 2024, they obtained approval from Puerto Rico's Health Dept. for Endari® (L-glutamine oral powder) to treat sickle cell disease. This achievement is a key step in Emmaus' goal to enhance the quality of life for sickle cell disease patients globally.
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts. The company is one of the early adopters of rational drug design. In December 2023, Vertex partnered with CRISPR Therapeutics to gain FDA approval for CASGEVY™, a cell therapy for sickle cell disease. This treatment targets patients over 12 suffering from recurrent crises.
Other players in the market are Pfizer Inc, Bristol Myers Squibb Company, Sangamo Therapeutics Inc, AbbVie Inc, Charles River Laboratories, and AstraZeneca plc.
Key Questions Answered in the Sickle Cell Disease Treatment Market Report
Sickle Cell Disease Treatment Market Overview
Treatment for sickle cell disease (SCD) aims to address symptoms such as anemia, pain, and organ damage. Sickle cell disease is a hereditary blood condition characterized by the presence of abnormal hemoglobin S that creates stiff, sickle-shaped red blood cells, resulting in obstruction and decreased oxygen supply to tissues. Mutations in the HBB gene result in deformed red blood cells, leading to aggregation and obstruction in blood vessels.
Managing sickle cell disease requires a comprehensive strategy that includes medication, blood transfusions, pain relief, and possible cures such as bone marrow transplants and new gene therapies. Patients frequently experience multiple hospital stays and need ongoing care to address the symptoms and complications linked to the illness.
In complicated cases of sickle cell disease, bone marrow or stem cell transplants may be needed for potential treatments. New possibilities are presented by emerging treatments such as gene therapies, voxelotor, and crizanlizumab. Several factors such as the rising patient population, significant investment from pharmaceutical companies, and an increasing focus on targeted therapies are likely to positively influence the market dynamics in the coming years.
Sickle Cell Disease Treatment Market Growth Drivers
Increasing Prevalence of Sickle Cell Disease Drives Market Growth
The increasing occurrence of sickle cell disease is fueling expansion in the market. Developed countries such as the United States and Europe also experience substantial occurrences because of migration and diversity. The Centers for Disease Control and Prevention’s May 2024 report states that sickle cell disease impacts around 100,000 people in the United States, out of which over 90% are non-Hispanic Black/African Americans and 3%-9% are Hispanics/Latinos. Life expectancy for those with sickle cell disease in the US is 20 years less than average. The need for innovative therapies and long-term care is growing due to the rising impact of the disease on children and adolescents, which is expected to lead to an increased demand for effective treatments.
Advancements in Gene Therapy and Technology are Likely to Boost Sickle Cell Disease Treatment Market Demand
Advancements in gene therapy and gene-editing techniques such as CRISPR-Cas9 are revolutionizing the treatment of sickle cell disease. In December 2023, the FDA approved Casgevy and Lyfgenia as the first cell-based gene therapies for sickle cell disease in patients 12 years and older. Casgevy also marks the first FDA-approved treatment utilizing novel genome editing technology. These treatments provide the potential for a permanent cure by altering or substituting the faulty hemoglobin gene. LentiGlobin and CRISPR-based treatments offer hope for patients with sickle cell disease with promising outcomes. With gene therapy becoming more available, the market is forecasted to expand quickly.
Sickle Cell Disease Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Shift Toward Curative Therapies
The market for treating sickle cell disease is moving towards curative methods such as stem cell transplantation instead of focusing on managing symptoms. Research is also exploring bone marrow and stem cell transplants as potential cures, despite obstacles such as limited donor availability. These developments are expected to drive market growth in the forecast period.
Increased Research on Hemoglobin Modifiers
There is a growing focus on studying hemoglobin modifiers such as voxelotor to change abnormal hemoglobin and decrease the deformation of red blood cells. More research is being done to create enhanced next-generation modifiers with better effectiveness and reduced side effects, broadening treatment choices for those with sickle cell disease. Focusing on modifying hemoglobin provides a less invasive option that is anticipated to make a big impact on the market for treating sickle cell disease, as opposed to gene and cell therapies.
Rising Interest in Combination Therapies
Combination treatments are being widely used in managing sickle cell disease to tackle its intricate characteristics. These treatments, including hydroxyurea, voxelotor, and crizanlizumab, focus on various facets of the illness to decrease vaso-occlusive episodes and lessen organ harm. Pharmaceutical companies are prioritizing clinical trials to investigate the synergistic impacts of these combinations, which is likely to aid in market growth.
Growing Demand for Pain Management Solutions
Effective pain control is essential in managing sickle cell disease as frequent crises result in intense pain. Recent treatments are focused on decreasing the frequency of pain, while non-drug methods like cognitive behavioral therapy are becoming more popular. These ground-breaking treatments are anticipated to have a positive impact on enhancing the clinical outcomes of patients with sickle cell disease.
Sickle Cell Disease Treatment Market Segmentation
The EMR’s report titled “Sickle Cell Disease Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment
- Pharmacotherapy
- Blood Transfusions
- Bone Marrow/ Stem Cell Transplantation
- Other Supportive Therapies
- Sickle Cell Anaemia
- Sickle Hemoglobin-C Disease
- Sickle Beta-Thalassemia
- Others
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
- United States
- EU-4 and the United Kingdom
- Japan
- India
Market Segmentation Based on the Treatment to Witness Growth
Based on the treatment, the market is divided into pharmacotherapy, blood transfusions, bone marrow/ stem cell transplantation, and other supportive therapies. Out of these, pharmacotherapy is expected to dominate the market because of its effectiveness, widespread availability, and cost-effectiveness. Medications such as hydroxyurea have been utilized for many years to treat symptoms of sickle cell disease. The management of sickle cell disease still heavily relies on medication, as other more invasive treatments such as bone marrow transplantation have limitations.
Market Share Based on Disease Type
Based on the disease type, the market is segmented into sickle cell anaemia, sickle hemoglobin-C disease, sickle beta-thalassemia, and others. Sickle cell anemia is the most prevalent and serious type of sickle cell disease, impacting many patients. Individuals with this disease deal with serious complications like painful crises and organ damage, leading to the need for extensive medical care.
Sickle Cell Disease Treatment Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
The United States is expected to dominate the market powered by government initiatives such as the National Sickle Cell Disease Program and newborn screening, which have enhanced the ability to diagnose and provide treatment at an early stage. Further, the market growth in the region is propelled by high healthcare spending and support from advocacy groups.
EU-4 and the United Kingdom are also poised to have a significant market share. Newborn screening and extensive healthcare services support individuals with sickle cell disease in the EU-4 (Germany, France, Italy, Spain) and the United Kingdom. The United Kingdom's NHS provides specialized medical services, as gene therapy research advances.
Additionally, the markets in Japan and India are rapidly expanding. Japan puts more emphasis on studying different genetic disorders and allocates substantial resources into researching gene therapy, while India deals with a high burden of sickle cell disease and works to enhance screening and access to treatment. The rise in strategic collaborations along with significant research funding is predicted to boost the development of India's sickle cell disease market in the forecast period.
Leading Players in the Sickle Cell Disease Treatment Market
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Novartis AG
Novartis AG is a Swiss pharmaceutical corporation that focuses on healthcare, producing prescription and generic drugs, as well as eye care products. Their products treat various diseases such as cancer, cardiovascular conditions, and respiratory illnesses. In April 2024, the FDA approved Novartis' Adakveo to reduce pain events in individuals with sickle cell disease. This medication helps decrease the frequency of vaso-occlusive crises in adults and children over 16 years old.
Bluebird Bio, Inc.
Bluebird Bio, Inc. is a biotechnology company based in Massachusetts. In December 2023, the company received FDA approval for LYFGENIA (lovo-cel) to treat sickle cell disease in patients aged 12 and older with a history of vaso-occlusive events. LYFGENIA is a one-time gene therapy designed to address the root cause of the disease and resolve vaso-occlusive events.
Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. develops treatments for rare diseases. In February 2024, they obtained approval from Puerto Rico's Health Dept. for Endari® (L-glutamine oral powder) to treat sickle cell disease. This achievement is a key step in Emmaus' goal to enhance the quality of life for sickle cell disease patients globally.
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts. The company is one of the early adopters of rational drug design. In December 2023, Vertex partnered with CRISPR Therapeutics to gain FDA approval for CASGEVY™, a cell therapy for sickle cell disease. This treatment targets patients over 12 suffering from recurrent crises.
Other players in the market are Pfizer Inc, Bristol Myers Squibb Company, Sangamo Therapeutics Inc, AbbVie Inc, Charles River Laboratories, and AstraZeneca plc.
Key Questions Answered in the Sickle Cell Disease Treatment Market Report
- What was the sickle cell disease treatment market value in 2024?
- What is the sickle cell disease treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the treatment?
- What is the market segmentation based on the disease type?
- What is the market breakup based on end user?
- What are the major factors aiding the sickle cell disease treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the sickle cell disease treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Sickle Cell Disease Treatment Market Overview: 8 Major Markets
- 3.1 Sickle Cell Disease Treatment Market Historical Value (2018-2024)
- 3.2 Sickle Cell Disease Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Sickle Cell Disease Treatment: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Sickle Cell Disease Treatment Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Sickle Cell Disease Treatment Market Landscape: 8 Major Markets*
- 8.1 Sickle Cell Disease Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Sickle Cell Disease Treatment Market: Product Landscape
- 8.2.1 Analysis by Treatment
- 8.2.2 Analysis by Disease Type
- 9 Sickle Cell Disease Treatment Market Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Sickle Cell Disease Treatment Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Sickle Cell Disease Treatment Market Segmentation: 8 Major Markets
- 12.1 Sickle Cell Disease Treatment Market (2018-2034) by Treatment
- 12.1.1 Market Overview
- 12.1.2 Pharmacotherapy
- 12.1.3 Blood Transfusions
- 12.1.4 Bone Marrow/ Stem Cell Transplantation
- 12.1.5 Others Supportive Therapies
- 12.2 Sickle Cell Disease Treatment Market (2018-2034) by Disease Type
- 12.2.1 Market Overview
- 12.2.2 Sickle Cell Anaemia
- 12.2.3 Sickle Hemoglobin-C Disease
- 12.2.4 Sickle Beta-Thalassemia
- 12.2.5 Others
- 12.3 Sickle Cell Disease Treatment Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Specialty Clinics
- 12.3.4 Ambulatory Surgical Centers
- 12.3.5 Others
- 12.4 Sickle Cell Disease Treatment Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Sickle Cell Disease Treatment Market (218-2034)
- 13.1 United States Sickle Cell Disease Treatment Market Historical Value (2018-2024)
- 13.2 United States Sickle Cell Disease Treatment Market Forecast Value (2025-2034)
- 13.3 United States Sickle Cell Disease Treatment Market (2018-2034) by Treatment
- 13.3.1 Market Overview
- 13.3.2 Pharmacotherapy
- 13.3.3 Blood Transfusions
- 13.3.4 Bone Marrow/ Stem Cell Transplantation
- 13.3.5 Others Supportive Therapies
- 13.4 United States Sickle Cell Disease Treatment Market (2018-2034) by Disease Type
- 13.4.1 Market Overview
- 13.4.2 Sickle Cell Anaemia
- 13.4.3 Sickle Hemoglobin-C Disease
- 13.4.4 Sickle Beta-Thalassemia
- 13.4.5 Others
- 13.5 United States Sickle Cell Disease Treatment Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Specialty Clinics
- 13.5.4 Ambulatory Surgical Centers
- 13.5.5 Others
- 14 EU-4 and United Kingdom Sickle Cell Disease Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Sickle Cell Disease Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Sickle Cell Disease Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Sickle Cell Disease Treatment Market (2018-2034) by Treatment
- 14.3.1 Market Overview
- 14.3.2 Pharmacotherapy
- 14.3.3 Blood Transfusions
- 14.3.4 Bone Marrow/ Stem Cell Transplantation
- 14.3.5 Others Supportive Therapies
- 14.4 EU-4 and United Kingdom Sickle Cell Disease Treatment Market (2018-2034) by Disease Type
- 14.4.1 Market Overview
- 14.4.2 Sickle Cell Anaemia
- 14.4.3 Sickle Hemoglobin-C Disease
- 14.4.4 Sickle Beta-Thalassemia
- 14.4.5 Others
- 14.5 EU-4 and United Kingdom Sickle Cell Disease Treatment Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals
- 14.5.3 Specialty Clinics
- 14.5.4 Ambulatory Surgical Centers
- 14.5.5 Others
- 15 Japan Sickle Cell Disease Treatment Market (218-2034)
- 15.1 Japan Sickle Cell Disease Treatment Market Historical Value (2018-2024)
- 15.2 Japan Sickle Cell Disease Treatment Market Forecast Value (2025-2034)
- 15.3 Japan Sickle Cell Disease Treatment Market (2018-2034) by Treatment
- 15.3.1 Market Overview
- 15.3.2 Pharmacotherapy
- 15.3.3 Blood Transfusions
- 15.3.4 Bone Marrow/ Stem Cell Transplantation
- 15.3.5 Others Supportive Therapies
- 15.4 Japan Sickle Cell Disease Treatment Market (2018-2034) by Disease Type
- 15.4.1 Market Overview
- 15.4.2 Sickle Cell Anaemia
- 15.4.3 Sickle Hemoglobin-C Disease
- 15.4.4 Sickle Beta-Thalassemia
- 15.4.5 Others
- 15.5 Japan Sickle Cell Disease Treatment Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals
- 15.5.3 Specialty Clinics
- 15.5.4 Ambulatory Surgical Centers
- 15.5.5 Others
- 16 India Sickle Cell Disease Treatment Market (218-2034)
- 16.1 India Sickle Cell Disease Treatment Market Historical Value (2018-2024)
- 16.2 India Sickle Cell Disease Treatment Market Forecast Value (2025-2034)
- 16.3 India Sickle Cell Disease Treatment Market (2018-2034) by Treatment
- 16.3.1 Market Overview
- 16.3.2 Pharmacotherapy
- 16.3.3 Blood Transfusions
- 16.3.4 Bone Marrow/ Stem Cell Transplantation
- 16.3.5 Others Supportive Therapies
- 16.4 India Sickle Cell Disease Treatment Market (2018-2034) by Disease Type
- 16.4.1 Market Overview
- 16.4.2 Sickle Cell Anaemia
- 16.4.3 Sickle Hemoglobin-C Disease
- 16.4.4 Sickle Beta-Thalassemia
- 16.4.5 Others
- 16.5 India Sickle Cell Disease Treatment Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals
- 16.5.3 Specialty Clinics
- 16.5.4 Ambulatory Surgical Centers
- 16.5.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Novartis AG
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 Pfizer Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 Bluebird Bio, Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 Emmaus Life Sciences, Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 Bristol Myers Squibb Company
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 23.7 Vertex Pharmaceuticals Incorporated
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Developments
- 23.7.5 Certifications
- 23.8 Sangamo Therapeutics, Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Developments
- 23.8.5 Certifications
- 23.9 AbbVie Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Developments
- 23.9.5 Certifications
- 23.10 Charles River Laboratories
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Developments
- 23.10.5 Certifications
- 23.11 AsraZeneca plc
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Developments
- 23.11.5 Certifications
- 24 Sickle Cell Disease Treatment Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
